Skip to content 
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein-coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts. more
| Time Frame | TECX | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | -4.08% | -0.26% | 0.42% |
| 1-Month Return | 11.88% | 1.2% | 1.02% |
| 3-Month Return | 18.33% | 3.86% | 4.93% |
| 6-Month Return | -11.25% | 14.37% | 7.32% |
| 1-Year Return | -30.7% | 6.82% | 12.16% |
| 3-Year Return | 11.3% | 20.71% | 71.63% |
| 5-Year Return | -84.17% | 37.78% | 76.95% |
| 10-Year Return | -94.29% | 135.17% | 252.5% |
| Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | - | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Cost of Revenue | 1.21M | 1.40M | 4.17M | 617.00K | 1.65M | [{"date":"2020-12-31","value":28.97,"profit":true},{"date":"2021-12-31","value":33.58,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":14.81,"profit":true},{"date":"2024-12-31","value":39.49,"profit":true}] |
| Gross Profit | (1.21M) | (1.40M) | (4.17M) | (617.00K) | (1.65M) | [{"date":"2020-12-31","value":-120700000,"profit":false},{"date":"2021-12-31","value":-139900000,"profit":false},{"date":"2022-12-31","value":-416600000,"profit":false},{"date":"2023-12-31","value":-61700000,"profit":false},{"date":"2024-12-31","value":-164500000,"profit":false}] |
| Gross Margin | - | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Operating Expenses | 119.02M | 15.61M | 32.83M | 44.65M | 58.02M | [{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":13.12,"profit":true},{"date":"2022-12-31","value":27.58,"profit":true},{"date":"2023-12-31","value":37.51,"profit":true},{"date":"2024-12-31","value":48.74,"profit":true}] |
| Operating Income | (120.23M) | (15.61M) | (32.83M) | (44.65M) | (58.02M) | [{"date":"2020-12-31","value":-12022800000,"profit":false},{"date":"2021-12-31","value":-1561000000,"profit":false},{"date":"2022-12-31","value":-3283000000,"profit":false},{"date":"2023-12-31","value":-4464800000,"profit":false},{"date":"2024-12-31","value":-5801500000,"profit":false}] |
| Total Non-Operating Income/Expense | - | 6.24M | 655.00K | 2.25M | 4.19M | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":10.5,"profit":true},{"date":"2023-12-31","value":36.13,"profit":true},{"date":"2024-12-31","value":67.12,"profit":true}] |
| Pre-Tax Income | (119.71M) | (8.93M) | (32.18M) | (42.82M) | (57.98M) | [{"date":"2020-12-31","value":-11971200000,"profit":false},{"date":"2021-12-31","value":-892700000,"profit":false},{"date":"2022-12-31","value":-3218000000,"profit":false},{"date":"2023-12-31","value":-4282300000,"profit":false},{"date":"2024-12-31","value":-5798200000,"profit":false}] |
| Income Taxes | - | - | - | 377.00K | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Income After Taxes | - | - | - | (43.20M) | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":-4320000000,"profit":false},{"date":"2024-12-31","value":"-","profit":true}] |
| Income From Continuous Operations | - | (8.93M) | (32.18M) | (42.82M) | (57.98M) | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-892700000,"profit":false},{"date":"2022-12-31","value":-3218000000,"profit":false},{"date":"2023-12-31","value":-4282300000,"profit":false},{"date":"2024-12-31","value":-5798200000,"profit":false}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Net Income | (119.71M) | (8.93M) | (32.18M) | (42.82M) | (57.98M) | [{"date":"2020-12-31","value":-11971200000,"profit":false},{"date":"2021-12-31","value":-892700000,"profit":false},{"date":"2022-12-31","value":-3218000000,"profit":false},{"date":"2023-12-31","value":-4282300000,"profit":false},{"date":"2024-12-31","value":-5798200000,"profit":false}] |
| EPS (Diluted) | (3.31) | (2.79) | (2.41) | (0.03) | (8.18) | [{"date":"2020-12-31","value":-331,"profit":false},{"date":"2021-12-31","value":-279,"profit":false},{"date":"2022-12-31","value":-241,"profit":false},{"date":"2023-12-31","value":-3,"profit":false},{"date":"2024-12-31","value":-817.64,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
| TECX | |
|---|---|
| Cash Ratio | 28.64 |
| Current Ratio | 29.15 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| TECX | |
|---|---|
| ROA (LTM) | -21.46% |
| ROE (LTM) | -32.21% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| TECX | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.03 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.97 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| TECX | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 0.00 |
| P/B | 1.56 |
| Price/FCF | NM |
| EV/R | 0.00 |
| EV/Ebitda | NM |
Tectonic Therapeutic, Inc. (TECX) share price today is $21.37
Yes, Indians can buy shares of Tectonic Therapeutic, Inc. (TECX) on Vested. To buy
Yes, you can purchase fractional shares of Tectonic Therapeutic, Inc. (TECX) via the Vested app. You can start investing in Tectonic Therapeutic, Inc. (TECX) with a minimum investment of $1.
You can invest in shares of Tectonic Therapeutic, Inc. (TECX) via Vested in three simple steps:
The 52-week high price of Tectonic Therapeutic, Inc. (TECX) is $31.12. The 52-week low price of Tectonic Therapeutic, Inc. (TECX) is $13.7.
The price-to-earnings (P/E) ratio of Tectonic Therapeutic, Inc. (TECX) is
The price-to-book (P/B) ratio of Tectonic Therapeutic, Inc. (TECX) is 1.56
The dividend yield of Tectonic Therapeutic, Inc. (TECX) is 0.00%
The market capitalization of Tectonic Therapeutic, Inc. (TECX) is $393.04M
The stock symbol (or ticker) of Tectonic Therapeutic, Inc. is TECX
Consider the share price of Tectonic Therapeutic, Inc. as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Tectonic Therapeutic, Inc. has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Tectonic Therapeutic, Inc. shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Tectonic Therapeutic, Inc. stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Tectonic Therapeutic, Inc. and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Tectonic Therapeutic, Inc. stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
